About 24 results found for searched term "Lib2-1" (0.129 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M10347 | Abemaciclib (LY2835219) | CDK |
| LY2835219 free base | ||
| Abemaciclib (LY2835219) is a best-in-class, selective and effective dual inhibitor of CDK4 and CDK6, which inhibits CDK4/CDK6 activity with IC50 of 2 nM and 10 nM respectively. | ||
| M15101 | Cemiplimab | PD-1/PD-L1 |
| Libtayo; REGN-2810; cemiplimab-rwlc | ||
| Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Cemiplimab blocks T-cell inactivation and boosts the immune system's antitumor response. | ||
| M52849 | Lib2-1 | IL Receptor/Related |
| Lib2-1, a macrocyclic peptide, is an IL-17C/IL-17RE interaction inhibitor. | ||
| M1807 | SCH727965 (dinaciclib) | CDK |
| Dinaciclib | ||
| SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. | ||
| M2911 | Riviciclib hydrochloride (P276-00) | CDK |
| Riviciclib hydrochloride | ||
| Riviciclib hydrochloride (P276-00) is an effective CDK inhibitor, inhibiting CDK9-CyclinT1, CDK4-cyclin D1, CDK1-Cyclinb with IC50 values of 20 nM, 63 nM, respectively. 79 nM. Riviciclib hydrochloride (P276-00) has anti-tumor activity against Cisplatin resistant cells. | ||
| M2913 | Palbociclib Isethionate | CDK |
| PD 0332991 isethionate | ||
| Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 2/3. | ||
| M8962 | Voruciclib | CDK |
| P1446A-05 | ||
| Voruciclib (P1446A-05) is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively. | ||
| M10033 | Trilaciclib | CDK |
| G1T28; G1T-28 | ||
| Trilaciclib (G1T28) is a potent first-in-class reversible CDK4/6 inhibitor with IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. | ||
| M10327 | Zotiraciclib | CDK |
| TG02; SB1317 | ||
| Zotiraciclib (TG02, SB1317) is an orally bioavailable, brain penetrant multi-kinase inhibitor of CDK2, JAK2, and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. | ||
| M10886 | Samuraciclib hydrochloride | CDK |
| Samuraciclib (ICEC0942, CT7001) is a novel oral CDK7 inhibitor with an IC50 of 40 nM. It has IC50 values for other CDK proteins such as CDK1, CDK2, CDK5 and CDK9 as 45, 15, 230 and 30 times higher than that of CDK7 IC50, respectively. ICEC0942 (CT7001) promotes cell cycle blocking and apoptosis. | ||
| M10930 | Dalpiciclib | CDK |
| SHR-6390 | ||
| Dalpiciclib (SHR-6390) is a highly selective, oral bioavailable inhibitor of CDK4/6 that is used against CDK4 (IC50=12.4 nM) and CDK6 (IC50=9.9 nM) is equivalent. SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb protein and inducing G1 cell cycle blocking. | ||
| M11249 | (+)-Enitociclib | CDK |
| (+)-BAY-1251152; (+)-VIP152 | ||
| (+) -enitociclib ((+) -bay-1251152) is an enantiomer of Bay-1251152 with optical rotation of (+). (+) -enitociclib is a potent selective CDK9 inhibitor with an IC50 of 3 nM. (+) -enitociclib has antitumor activity. | ||
| M13398 | BSJ-03-204 | PROTAC |
| BSJ-03-204 is a Cereblon ligand linked to THE CDK ligand PROTAC, which is an effective, selective cdK4/6 dual inhibitor based on Palbociclib. The IC50 of CDK4/D1 and CDK6/D1 were 26.9 nM and 10.4 nM, respectively. | ||
| M13596 | Atuveciclib | CDK |
| BAY-1143572 | ||
| Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC50 of 13 nM. | ||
| M13600 | Abemaciclib metabolite M20 | CDK |
| LSN3106726 | ||
| Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor for the treatment of cancer. | ||
| M13602 | Abemaciclib metabolite M18 hydrochloride | CDK |
| LSN3106729 hydrochloride | ||
| Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. | ||
| M13604 | Lerociclib dihydrochloride | CDK |
| G1T38 dihydrochloride | ||
| Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively. | ||
| M20983 | Barnidipine | Calcium Channel |
| Libradin, Mepirodipine, Vasexten, YM-09730-5, Cyress, Hypoca, Oldeca | ||
| Barnidipine (Libradin, Mepirodipine, Vasexten, YM-09730-5, Cyress, Hypoca, Oldeca) is an antihypertensive drug that belongs to the dihydropyridine (DHP) group of calcium antagonist (CaA) with Ki of 0.21 nM for [3H]nitrendipine binding sites. | ||
| M21177 | (-)-Enitociclib | CDK |
| (-)-BAY-1251152; (-)-VIP152 | ||
| (-)-Enitociclib ((-)-BAY-1251152) is an enantiomer of BAY-1251152 with a (-) spin. BAY-1251152 is a potent and highly selective inhibitor of cell cycle-dependent protein kinase (PTEF/CDK9). | ||
| M28667 | (±)-Enitociclib | CDK |
| (±)-BAY-1251152; (±)-VIP152 | ||
| (±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. | ||
| M28894 | Samuraciclib | CDK |
| CT7001; ICEC0942 | ||
| Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects. | ||
| M29520 | BSJ-04-132 | PROTAC |
| BSJ-04-132 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC50s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity. | ||
| M56975 | Enitociclib | Others |
| Enitociclib (VIP152; BAY-1251152) is a selective CDK9 inhibitor. | ||
| M58388 | Abemaciclib metabolites M2 | CDK |
| LSN2839567 | ||
| Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
